The Worldwide Gastric Cancer Therapy Market to 2024 - Introduction of Novel Therapies for Metastatic Stomach Cancer Drives Growth

Friday, 28. June 2019 12:15

Dublin, June 28, 2019 (GLOBE NEWSWIRE) -- The "Gastric Cancer Therapy Market - Growth, Trends, and Forecast (2019 - 2024)" report has been added to's offering.

The rising incidences of stomach cancer are one of the major factors driving the growth of the market.

Key Market Trends

Chemotherapy Expected to Grow with a High CAGR During the Forecasted Period

Chemotherapy is the most common form of therapeutics used to stop or slow the growth of cancer cells. Surgery and radiation therapy works by removing, killing, or damaging the cancer cells in a certain area, but chemotherapy works throughout the whole body. This means chemotherapy can kill and damage cancer cells that have spread to other parts of the body, far away from the original tumor. Even though chemotherapy has many associated side effects, it is still the therapy of choice among most oncologists, worldwide. It is also cheap, when compared to immunotherapies, and is administered either through an intravenous route or orally.

Some of the chemotherapy drugs used in the treatment of stomach cancer are 5-FU, Capecitabine, Carboplatin, Cisplatin, Docetaxel, Epirubicin, Irinotecan, Oxaliplatin, and Paclitaxel. Stomach cancer prevalence is expected to increase in the coming years, and the rising number of cancer cases is driving the chemotherapy market, which is expected to grow further during the forecast period. Chemotherapy-based drugs have been the choice of treatment for decades, and have been the main treatment options for several types of cancer. Hence, the market is expected to witness substantial growth during the forecast period.

North America Dominates the Market and is Expected to do Same in the Forecast Period

North America is expected to dominate the overall market, throughout the forecast period. In the North America region, the United States holds the largest market share. This is attributed to the rising prevalence of stomach cancer, and the availability of advanced technology in cancer research and treatment centers. The region is well developed in terms of availability of advanced technologies to treat the cancers, along with medical devices companies pushing themselves to compete with established players across the United States and Canada. People in large numbers from developing economies do travel regularly in case of cancer-related treatment. Such factors boost the growth of this market.

Competitive Landscape

The gastric cancer therapy market is competitive and consists of a few major players. In terms of market share, few of the major players currently dominate the market. Some of the major players of the market are F. Hoffmann-La Roche, Bristol-Myers Squibb, Pfizer, Merck & Co, and Celltrion, are among others.

Topics Covered




4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Burden of Gastric Cancer
4.2.2 Introduction of Novel Therapies for Metastatic Stomach Cancer
4.3 Market Restraints
4.3.1 High Cost of Cancer Therapy & Side Effects of Cancer Drugs
4.4 Porter's Five Force Analysis

5.1 Therapy Type
5.1.1 Surgery
5.1.2 Chemotherapy
5.1.3 Targeted Therapy
5.1.4 Immuno Therapy
5.1.5 Radiation Therapy
5.2 End-users
5.2.1 Hospitals & Specialty Clinics
5.2.2 Cancer Research & Treatment Centers
5.2.3 Ambulatory Surgery Centers
5.3 Geography
5.3.1 North America US Canada Mexico
5.3.2 Europe Germany UK France Italy Spain Rest of Europe
5.3.3 Asia Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.3.4 Middle East and Africa GCC South Africa Rest of Middle East and Africa
5.3.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 Bristol-Myers Squibb
6.1.2 Celltrion
6.1.3 Eli Lilly and Company
6.1.4 F. Hoffmann-La Roche Ltd.
6.1.5 GlaxoSmithKline PLC
6.1.6 Imugene Limited
6.1.7 Novartis AG
6.1.8 Merck & Co. Inc.
6.1.9 Otsuka Holdings Co. Ltd.
6.1.10 Pfizer Inc.
6.1.11 Sanofi


For more information about this report visit

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

         Laura Wood, Senior Press Manager
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
Related Topics: Oncology Drugs 

Primary Logo

Related Links: 
Copyright GlobeNewswire, Inc. 2016. All rights reserved.
You can register yourself on the website to receive press releases directly via e-mail to your own e-mail account.